Caribou Biosciences, INC. (CRBU) — SEC Filings

Overview

Caribou Biosciences, INC. (CRBU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 31, 2026: On March 31, 2026, Caribou Biosciences, Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibits. The filing includes an iXBRL 8-K document and exhibits, but no specific financial figures or material events were disclosed in the provid

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 36 neutral. The dominant filing sentiment for Caribou Biosciences, INC. is neutral.

Filing Type Overview

Caribou Biosciences, INC. (CRBU) has filed 14 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13D/A, 10 SC 13G/A, 3 SC 13G, 1 8-K/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

• Caribou Biosciences Files 8-K — 8-K · Mar 31, 2026 Risk: low
  On March 31, 2026, Caribou Biosciences, Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibit
• Caribou Biosciences' Losses Widen Amid Impairment Charges — 10-Q · Nov 12, 2025 Risk: high
  Caribou Biosciences, Inc. (CRBU) reported a net loss of $121.6 million for the nine months ended September 30, 2025, an increase from $113.6 million in the same
• Caribou Biosciences Files 8-K on Financials and Operations — 8-K · Nov 3, 2025 Risk: medium
  Caribou Biosciences, Inc. filed an 8-K on November 3, 2025, reporting on its results of operations and financial condition. The filing also included disclosures
• Caribou Biosciences' Losses Widen Amidst R&D Spend — 10-Q · Aug 12, 2025 Risk: high
  Caribou Biosciences, Inc. reported a net loss of $49.2 million for the three months ended June 30, 2025, an increase from the $40.5 million net loss for the sam
• Caribou Biosciences Files 8-K Report — 8-K · Jun 23, 2025 Risk: low
  On June 18, 2025, Caribou Biosciences, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial tr
• Caribou Biosciences Files 8-K on Shareholder Votes & Financials — 8-K · Jun 13, 2025 Risk: low
  On June 12, 2025, Caribou Biosciences, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The
• Caribou Biosciences Q1 2025 10-Q Filing — 10-Q · May 8, 2025 Risk: medium
  Caribou Biosciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on biological products, reported its financial s
• Caribou Biosciences Files 2025 Proxy Statement — DEF 14A · Apr 25, 2025 Risk: low
  Caribou Biosciences, Inc. filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its 2025 Annual Meeting of Stockholders. The filing covers the f
• Caribou Biosciences Files 8-K on Financials and Operations — 8-K · Apr 24, 2025 Risk: medium
  On April 24, 2025, Caribou Biosciences, Inc. filed an 8-K report. The filing indicates the company is reporting on its results of operations and financial condi
• Caribou Biosciences Files 2024 10-K — 10-K · Mar 10, 2025 Risk: medium
  Caribou Biosciences, Inc. filed its 2024 10-K on March 10, 2025, reporting its fiscal year ended December 31, 2024. The company, focused on biological products,
• Caribou Biosciences Files 8-K — 8-K · Jan 13, 2025 Risk: low
  On January 12, 2025, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits
• Caribou Biosciences Files 8-K on Officer/Director Changes — 8-K · Jan 2, 2025 Risk: medium
  On January 2, 2025, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns the departure of directors or certain officers, the election of
• Caribou Biosciences (CRBU) Sees 13D Filing Amendment — SC 13D/A · Dec 6, 2024 Risk: medium
  On December 6, 2024, Rachel E. Haurwitz filed an amendment to Schedule 13D for Caribou Biosciences, Inc. The filing indicates a change in beneficial ownership o
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Caribou Biosciences Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Caribou Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its operat
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G/A Filing — SC 13G/A · Oct 17, 2024
• Caribou Biosciences Files 8-K/A Amendment — 8-K/A · Sep 27, 2024 Risk: medium
  Caribou Biosciences, Inc. filed an 8-K/A amendment on September 27, 2024, related to events occurring on September 1, 2024. The filing pertains to the departure
• Caribou Biosciences Announces Board and Executive Changes — 8-K · Sep 3, 2024 Risk: medium
  Caribou Biosciences, Inc. announced on September 1, 2024, changes in its board of directors and executive compensation arrangements. The filing details the depa
• Caribou Biosciences Files 8-K Report — 8-K · Aug 12, 2024 Risk: low
  On August 12, 2024, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financia
• Caribou Biosciences 10-Q: Q2 2024 Financial Update — 10-Q · Aug 6, 2024 Risk: medium
  Caribou Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The filing details
• Caribou Biosciences Files 8-K on Operations and Finances — 8-K · Jul 16, 2024 Risk: low
  On July 16, 2024, Caribou Biosciences, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also covers costs associated
• Caribou Biosciences Files 8-K on Shareholder Vote & Financials — 8-K · Jun 14, 2024 Risk: low
  On June 13, 2024, Caribou Biosciences, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements. The co
• Caribou Biosciences (CRBU) Files 8-K Report — 8-K · Jun 3, 2024 Risk: low
  On June 2, 2024, Caribou Biosciences, Inc. (CRBU) filed an 8-K report. The filing indicates the company's principal executive offices are located at 2929 7th St
• Caribou Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
  Caribou Biosciences, Inc. (CRBU) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Caribou Biosciences reported financial results for the quarter end
• Caribou Biosciences Announces 2024 Annual Meeting of Stockholders on June 13 — DEF 14A · Apr 25, 2024 Risk: low
  Caribou Biosciences, Inc. (CRBU) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Caribou Biosciences will hold its 2024 Annual Meeting of Stoc
• Caribou Biosciences Files 8-K Report — 8-K · Apr 4, 2024 Risk: low
  On April 4, 2024, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no spec
• Caribou Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 11, 2024 Risk:
  Caribou Biosciences, Inc. (CRBU) filed a Annual Report (10-K) with the SEC on March 11, 2024. Caribou Biosciences, Inc. filed its 2023 Form 10-K on March 11, 20
• SC 13G Filing — SC 13G · Feb 23, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• BlackRock Amends Caribou Biosciences Stake Filing — SC 13G/A · Jan 25, 2024
  BlackRock, Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Caribou Biosciences, Inc. common stock as of December 31, 2023. This
• State Street Corp. Amends Caribou Biosciences Stake Filing — SC 13G/A · Jan 25, 2024
  State Street Corporation, a major financial institution, filed an amended Schedule 13G/A on January 25, 2024, indicating its ownership of Caribou Biosciences In
• Caribou Biosciences Files Routine 8-K on Jan 7 Event — 8-K · Jan 8, 2024
  Caribou Biosciences, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing is a routine disclosure under Regula
• Avidity Partners Takes 6.36M Share Stake in Caribou Biosciences — SC 13G · Jan 8, 2024
  Avidity Partners Management LP, a Delaware-based investment firm, reported acquiring shared voting and dispositive power over 6,360,212 shares of Caribou Biosci

Risk Profile

Risk Assessment: Of CRBU's 24 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Caribou Biosciences, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $7.2M
• Net Income: -$121.6M
• EPS: N/A
• Debt-to-Equity: 0.37
• Cash Position: $159.2M
• Operating Margin: N/A
• Total Assets: $195.0M
• Total Debt: $53.1M

Key Executives

• Rachel E. Haurwitz
• FELIX ADLER
• Rachel Haurwitz, Ph.D.
• Dara Richardson-Heron, M.D.
• Natalie Sacks, M.D.

Industry Context

Caribou Biosciences operates in the highly competitive and rapidly evolving biopharmaceutical sector, specifically focusing on gene editing and cell therapy. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Key trends include advancements in CRISPR technology, the growing promise of CAR-T therapies for various cancers, and increasing collaboration between biotech firms and larger pharmaceutical companies.

Top Tags

sec-filing (5) · disclosure (4) · Biotechnology (4) · corporate-governance (4) · financials (4) · filing (4) · 10-Q (4) · 8-k (3) · financial-condition (3) · operations (3)

Key Numbers

• Net Loss (9 months): $121.6M — Increased from $113.6M in 2024, indicating widening losses.
• Accumulated Deficit: $570.0M — Significant historical losses, growing from $448.4M at Dec 31, 2024.
• Licensing & Collaboration Revenue (9 months): $7.2M — Decreased from $7.9M in 2024, showing a decline in core revenue.
• Impairment Charges (9 months): $12.15M — New significant charge in 2025, impacting profitability.
• Impairment of Equity Investment (9 months): $9.16M — New significant charge in 2025, further impacting profitability.
• Research & Development Expenses (9 months): $85.6M — Decreased from $99.7M in 2024, potentially slowing drug development.
• Cash, Cash Equivalents, & Marketable Securities: $159.2M — Sufficient for 12 months, but a significant drop from $249.4M at Dec 31, 2024.
• Cash Used in Operating Activities (9 months): $90.2M — High cash burn, though an improvement from $102.7M in 2024.
• Net Loss (Q2 2025): $49.2M — Increased from $40.5M in Q2 2024, indicating widening losses.
• Net Loss (H1 2025): $97.7M — Increased from $79.8M in H1 2024, showing accelerated losses.
• Revenue (Q2 2025): $1.5M — Decreased from $2.1M in Q2 2024, signaling revenue decline.
• Operating Expenses (Q2 2025): $50.7M — Increased from $42.6M in Q2 2024, driven by R&D.
• Cash & Equivalents (June 30, 2025): $250.3M — Decreased from $300.1M at Dec 31, 2024, indicating significant cash burn.
• SEC File Number: 001-40631 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 45-3728228 — Company's tax identification number.

Frequently Asked Questions